The anti-BCMA CAR T-cell therapy bb2121 looks extremely promising in multiple myeloma (MM). Here, Noopur Raje, MD, of Massachusetts General Hospital Cancer Center, Boston, MA, discusses the results of CRB-401 (NCT02658929), a first-in-human trial of idecabtagene vicleucel (formerly bb2121) in relapsed/refractory MM, which were presented at the American Society of Oncology (ASCO) 2018 Annual Meeting in Chicago, IL. Prof. Raje also highlights avenues for further study and the key questions that remain to be answered.

свернуть